Studying the Mechanism of Gvax as a Therapeutic Vaccine and Using Prime/Boost Strategy to Enhance the Efficacy of Gvax Vaccine Apply in the Treatment of Cervical Cancer in the Mouse Model

Using of autologous cancer cells to treat cancer is rapid development trend in Clinical trail. Tumor cells that were genetically engineered to be vaccine can effectively induce T cell activation, the proliferation of specific anti-tumor antigen. In the previous project, we modified codon usage of GM-CSF of mice but without changing amino acid sequence and enhanced the expression amount of the protein. By using lentivirus vectors, we transfected mcGM-CSF into HPV oncogenic E6/E7 of mouse cell line, TC-1. Previous results have shown TC-1 cells genetically engineered to produce GM-CSF (GVAX vaccine) as prophylactic vaccination facilitated efficacy by promoting the development and prolongation of both humoral and cellular immunity in a murine model. In this project, we will use this GVAX as a therapeutic vaccine and heterologous Prime/Boost strategy improve the efficacy of GVAX. Ｗe will study the correlation of immune response against tumor between Treg、MDSC and IKDC in the tumor-bearing model. From the results of this project, we will understand the immune response produced by therapeutic vaccines in animal models and apply these findings to clinical treatment. Through the results of this project, we will understand the immune response produced by therapeutic vaccines in animal models and apply these findings to clinical treatment.

Project ID:PC10608-2349
External Project ID:MOST106-2314-B182-058